Synapse - GME, Medicine

Results (1538)

A niche driven mechanism determines response to ATRA and a mutation-independent therapeutic approach for MDS and AML

Meeting Abstract

Mosialou, I.; Ali, A. M.; Cuesta-Dominguez, A.; Labella, R.; Vgenopoulou, V.; Bisikirska, B.; Galan-Diez, M.; Wang, A. Q.; Bewersdorf, J. P.; Liang, C.; more...
Blood (2024)

Fulltext@MSK | Save

Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation

Meeting Abstract

Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
Blood (2024)

Fulltext@MSK | Save

Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma

Meeting Abstract

Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
Blood (2024)

Fulltext@MSK | Save

Treatment outcomes of patients treated with venetoclax-obinutuzumab therapy vs BTKi therapies in 1L CLL: An international real-world study

Meeting Abstract

Lamanna, N.; Brown, J. R.; Ujjani, C. S.; Eyre, T. A.; Manzoor, B.; Ghosh, N.; Roeker, L.; Davids, M. S.; Coombs, C. C.; Skarbnik, A. P.; more...
Blood (2024)

Fulltext@MSK | Save

Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities

Meeting Abstract

Boussi, L.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Aguirre, L. E.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; DeAngelo, D. J.; Stone, R. M.; more...
Blood (2024)

Fulltext@MSK | Save

Comparative analysis of outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients harboring very-high risk cytogenetics

Meeting Abstract

Aguirre, L. E.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; Deangelo, D. J.; Stone, R. M.; more...
Blood (2024)

Fulltext@MSK | Save

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with relapsed or refractory, splicing factor-mutant myeloid malignancies

Meeting Abstract

Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A. T.; Sallman, D.; Patel, M.; Stevens, D. A.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
Blood (2024)

Fulltext@MSK | Save

Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction

Meeting Abstract

Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
Blood (2024)

Fulltext@MSK | Save

Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma

Meeting Abstract

Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
Blood (2024)

Fulltext@MSK | Save

Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma - International, multi-center real-world experience

Meeting Abstract

Luttwak, E.; Kambhampati, S.; Drill, E.; Ganesan, N.; Hofstetter, L.; Gurion, R.; Aumann, S.; Haran, A.; Geva, M.; Panossian, M.; more...
Blood (2024)

Fulltext@MSK | Save